• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.
By BRET JENSEN
Oct 04, 2017 | 02:30 PM EDT
Stocks quotes in this article: TEVA, MYL, AGN, PFE, VRX

So far, 2017 has been a good one for the pharma and biotech sectors despite the lowest level of merger-and-acquisition activity in many years. The biotech sector is up about 20% after underperforming the market significantly in the 18 months leading up to the start of this year. However, one large company that has not participated in the rally is leading generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA) .

Teva's stock has seen nearly two-thirds of its value disappear over the 12 months. The wounds are largely self-inflicted.

Under previous leadership the company pursued an aggressive growth strategy via acquisition. First, it was rebuffed in an attempt to take over competitor Mylan (MYL) . When that pursuit did not pan out, it brokered a deal to buy the generic drug business of Action Alerts PLUS holding Allergan plc (AGN) , which at the time was itself working to be part of a megamerger with Pfizer Inc. (PFE) . Allergan's hook-up attempt finally was derailed by the Treasury Department in April 2016.

Teva ended up paying $40 billion for Allergan's generic divisions, of which around 80% was in cash. The company took on a great deal of debt to enable this transaction. The Israeli-based drug colossus could not have picked a worse time to double down in generic drugs, where it already was the market leader. While the 2016 election was full of rhetoric around drug price gouging, what was happening on the ground in the generic space was quite the opposite.

These trends got worse when the new administration appointed new leadership at the U.S Food and Drug Administration (FDA). Under the new commissioner, focus is shifting in the world of biotech and pharma. The agency is quite determined to make new drug development easier and less costly. At the same time, it is pushing hard to bring more competition to drugs that have come off patent.

The FDA has stated recently that it wants to see at least three manufacturers for each generic drug. The additional competition could force more price deflation on the industry.

Finally, Teva is going to face additional competition around its multiple sclerosis drug Copaxone, from which it gets around 10% of overall sales. Teva's stock was down more than 10% this morning on reports of the FDA's approval of Mylan's generic version of the drug.

Teva has started to take steps to address its challenges. It slashed its dividend to reduce expenses and expand cash flow to pay down debt and will make small divestitures toward that end. It also just brought in new CEO Kare Schultz, who is well-respected in the industry. The shares had gotten a bit of a boost from that recent decision as Teva started to address concerns the company was rudderless.

I have retained some shares in Teva, but I am not adding to that stake for the time being. I don't think the company is a version of Valeant Pharmaceuticals International Inc. (VRX) . However, Teva is going to take time to turn around and probably will be dead money until it shows signs of doing so under new leadership. I much prefer Allergan, which got the better end of its transaction with Teva, as well as numerous other plays in the large-cap pharma space.

This commentary originally appeared on Real Money Pro at 11:30 on Oct. 4. Click here to learn about this dynamic market information service for active traders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long AGN and TEVA.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long AGN.

TAGS: Investing | U.S. Equity | Healthcare | Corporate Governance | Stocks

More from Healthcare

Let's See How These Three Dividend Aristocrats Stack Up

Chris Versace
Dec 10, 2019 11:30 AM EST

Two food-related names and one in health care look like promising investments right now.

Cooper Cos. Can Rally Further After Some Sideways Consolidation

Bruce Kamich
Dec 5, 2019 2:42 PM EST

Time to review the charts and indicators.

This Dividend Stock Is Tipping the Scales for Investors

Chris Versace
Dec 5, 2019 2:08 PM EST

As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.

Avita Medical Could Double in 2020 but Not Without Risk

Bruce Kamich
Dec 5, 2019 9:53 AM EST

A 'promising' stock.

Raise Stops on NovoCure

Bruce Kamich
Dec 4, 2019 2:55 PM EST

NVCR's prices are poised to head higher in the months ahead.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:55 AM EST BOB LANG

    Strength in Semis and Banks

    Seeing some really good power in the semis today a...
  • 09:16 AM EST CHRIS VERSACE

    Dual Dividend Gift

    Coming up soon on Real Money Pro.
  • 11:02 AM EST BOB LANG

    Added Some Peloton

    This stock is starting to gain some traction, the ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login